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Abstract
Genetic and epidemiological evidence has suggested that genetic factors are important in schizophrenia, although its
pathophysiology is poorly understood. This study used whole-exome sequencing to investigate potential novel
schizophrenia-causing genes in a Japanese family containing several members affected by severe or treatment-
resistant schizophrenia. A missense variant, chr12:132064747C>T (rs200626129, P2805L), in the E1A-binding protein
P400 (EP400) gene completely segregated with schizophrenia in this family. Furthermore, numerous other EP400
mutations were identified in the targeted sequencing of a schizophrenia patient cohort. We also created two lines of
Ep400 gene-edited mice, which had anxiety-like behaviours and reduced axon diameters. Our findings suggest that
rs200626129 in EP400 is likely to cause schizophrenia in this Japanese family, and may lead to a better understanding
and treatment of schizophrenia.
Introduction
Schizophrenia is a severe and chronic neuropsychiatric
disorder1,2 with numerous psychotic symptoms, including
hallucinations and delusions3–6. Schizophrenia is usually
treated with antipsychotics, although ~30% of cases respond
poorly, which is termed treatment-resistant schizophrenia
(TRS)1,7. Because of these clinical aspects, schizophrenia is a
major cause of global disease burden8.
The pathophysiology of schizophrenia remains unclear. A
number of genetic and epidemiological studies suggest that
genetic factors play an important role in its pathogenesis,
and its heritability estimate is 0.819. Although genome-wide
association studies (GWAS) have identified >150
schizophrenia-associated polymorphisms10, no specific var-
iants with direct functional effects have been reported11.
Furthermore, no common variant has an individually large
effect, which is expected considering the selection pressures
of impaired reproductive fitness associated with schizo-
phrenia, and considering that the majority of risk cannot be
accounted for by the associated genes reported to date12,13.
Rare genetic variants detected by whole-exome sequencing
(WES) or whole-genome sequencing (WGS) using next-
generation sequencing (NGS) have demonstrated that the
RNA-binding motif 12 (RBM12) gene, the SET domain
containing 1 A (SETD1A) gene, and the solute carrier family
6 member 1 (SLC6A1) gene are high-risk factors14–17. The
functional consequences of these rare variants are expected
to be more readily interpretable18.
Using WES, the present study identified a unique mis-
sense variant in the E1A-binding protein P400 (EP400)
© The Author(s) 2021
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Shinji Ono (shinji1231zzz@yahoo.co.jp) or Koh-
ichiro Yoshiura (kyoshi@nagasaki-u.ac.jp)
1Department of Neuropsychiatry, Unit of Translation Medicine, Nagasaki
University Graduate School of Biomedical Sciences, Nagasaki, Japan
2Child and Adolescent Psychiatry Community Partnership Unit, Nagasaki
University Hospital, Nagasaki, Japan


































gene in a Japanese family in which several members were
affected by severe schizophrenia/TRS. Next, the fre-
quencies of rare EP400 variants were compared between
sporadic schizophrenia cases and controls. We also gen-
erated Ep400 gene-edited mice using clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9.
These mice developed anxiety-like behaviours and ultra-
structural abnormalities in the central nervous system
(CNS). We report here an EP400/Ep400 variant that eli-
cited abnormalities in neurobehaviour, which may lead to
schizophrenia.
Subjects and methods
Clinical presentation in a Japanese family
Three first-generation family members were diagnosed
with schizophrenia. One (Fig. 1a, I-9) had consulted a
psychiatric hospital because of auditory hallucinations
and delusions at 47 years old and was diagnosed with
schizophrenia. Her elder sister and brother (I-3 and I-4,
respectively) also had auditory hallucinations and delu-
sions and were hospitalised more than once; however,
their medical records were not preserved. Seven second-
generation family members (II-2, II-3, II-5, II-10, II-12, II-
13, and II-17) were diagnosed with schizophrenia and
treated with antipsychotic medications. Two of these
second-generation patients (II-3 and II-17) were diag-
nosed with TRS19 and required multiple long-term hos-
pitalisations, but were not treated with clozapine or
electroconvulsive therapy. Furthermore, two third-
generation family members were diagnosed with schizo-
phrenia (III-2 and III-3). III-2 refused medical care and
medication. None of the patients had neurological
abnormalities by standard neurological exams or comor-
bidities. All subjects in the family were evaluated by two
or more psychiatrists. Diagnoses of psychiatric diseases
were made with reference to the International Classifi-
cation of Diseases, Tenth Revision (ICD-10) and the
Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5). A detailed clinical presentation of
the Japanese family is summarised in Table 1.
DNA extraction
Of the 10 family members recruited, 7 were affected (I-
9, II-3, II-5, II-12, II-17, II-2, and III-3) and 3 were
unaffected (I-13, II-11, and II-20) by schizophrenia (Fig.
1a). After obtaining written consent, 10 mL of peripheral
blood was collected from individuals. Genomic DNA was
extracted from peripheral blood leukocytes using a
QIAamp DNA Midi Kit (Qiagen, Hilden, Germany).
WES
We assessed DNA quality using a NanoDrop 2000
(Thermo Fisher Scientific, Waltham, MA, USA) and a
Qubit fluorometer for nucleic acid quantification
(Thermo Fisher Scientific). We performed WES for the
seven affected and three unaffected individuals (Fig. 1a)
using a SureSelect Exome Target Enrichment System v5
(Agilent Technologies, Santa Clara, CA, USA) followed by
paired-end sequencing on a HiSeq 2500 (Illumina, San
Diego, CA, USA). Mean depths and coverage rates are
summarised in Supplementary Table 1.
Sequencing data analysis
Fastq format files were generated using bcl2fastq software.
Novoalign software (Novocraft Technologies, Kuala Lum-
pur, Malaysia) was used to align reads on the hg38/GRCh38
human reference genome sequence. Aligned reads were
sorted using Novosort software (Novocraft Technologies)
and subjected to polymerase chain reaction (PCR) marking
and optical duplication using MarkDuplicates in the Picard
tools package (http://broadinstitute.github.io/picard/). The
Genome Analysis Toolkit (GATK)20 was used to perform
local realignment (GATK IndelRealigner), and variant call-
ing (GATK HaplotypeCaller) was implemented in an in-
house workflow management tool21. Single nucleotide var-
iations (SNVs) and insertions/deletions (indels) were anno-
tated using ANNOVAR software22.
WES variant filtering
Substitutions meeting the following criteria were con-
sidered ‘deleterious’: (1) mutations: stop-gain, stop-loss,
nonsynonymous, or splice-site mutations according to
GENCODE basic 33, downloaded from the UCSC Genome
Browser (https://genome.ucsc.edu); and (2) alternative
allele frequencies of ≤0.5% at mutation loci in the following
databases: 4.7KJPN data of allele and genotype frequency
panels from 4773 Japanese individuals (https://jmorp.
megabank.tohoku.ac.jp/202001/variants); genome aggre-
gation database (gnomAD) v2.1.1 and v3 (https://gnomad.
broadinstitute.org);23 and Human Genomic Variation
Database (HGVD) v2.3 exome data from Japanese indivi-
duals (http://www.hgvd.genome.med.kyoto-u.ac.jp/index.
html)24. Two deleterious variants were shared among the
affected individuals (Supplementary Table 2). We excluded
rs768213554 in strawberry notch homolog 1 (SBNO1) gene
from the candidates because it was found in the cohort of
445 Japanese controls. Consequently, we considered the
rs200626129 variant in EP400 as the potential pathogenic
variant of our family. The WES variant filtering process is
summarised in Supplementary Table 3.
Sanger sequencing
Sanger sequencing confirmed that one variant was
shared among all of the affected individuals and was
absent in the three unaffected individuals. Primers were
designed using Primer3:25 chr12:132064747; C>T, for-
ward, 5′-TCATCAAAATGCAGAAGCAGA-3′, reverse,
5′-TCATCAAAATGCAGAAGCAGA-3′. Genomic DNA
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Fig. 1 Japanese family with multiple individuals affected by schizophrenia. a Japanese family with multiple individuals affected by
schizophrenia. Black symbols represent individuals diagnosed with schizophrenia. b Segregation of the missense mutation (chr12: 132064747; C>T on
hg38, p.P2805L in ENST00000389561.7) in EP400 with schizophrenia. c The position of the familial missense mutation in the EP400 gene. d The CaN-XT
algorithm in PONDR was used to predict the effect of p.P2805L on the EP400 protein. e EP400 deleterious variants in Japanese individuals with or
without schizophrenia. Rare variants are represented by lollipops, and counts of alleles with variants in the cases (top panel) and controls (bottom
panel) are shown. Novel variant= novel variant in all databases; ultra-rare variant= variants with MAF < 0.001 in any database; rare variant= variants
with 0.001 < MAF < 0.005 in any database.
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(5 ng) was amplified using KOD FX Neo polymerase
(Toyobo, Osaka, Japan) by PCR in 20-µL reactions. PCR
products were purified using AMPureXP® (Agencourt,
Beverly, MA, USA) and sequencing reactions were per-
formed using a BigDye Terminator Cycle Sequencing Kit
v3.1 (Applied Biosystems, Foster City, CA, USA). After
purification using CleanSEQ (Agencourt), DNA frag-
ments were run and separated on an ABI Genetic Ana-
lyzer 3130 (Applied Biosystems).
Mutational analysis of Japanese inpatient schizophrenia
case–control groups
Samples from 285 sporadic, inpatient schizophrenia
patients in Japan, who had been diagnosed by psychiatrists
in accordance with the DSM-5 or ICD-10, and 445 con-
trol samples were collected. For the schizophrenia asso-
ciation test using variants in the EP400 locus, we
performed target sequencing using a SeqCap EZ Choice
Library (Roche NimbleGen, Madison, WI, USA) accord-
ing to the manufacturer’s protocol. Prepared libraries
were sequenced using a HiSeq2500 (Illumina). Sub-
sequent analyses were performed using the hg19/GRCh37
human reference genome sequence, following the
“sequencing data analysis” section. CrossMap (http://
crossmap.sourceforge.net)26 was used to convert data to
hg38/GRCh38 human reference genome sequence
assemblies.
In silico analysis of rs200626129 in EP400
To analyse potential functional changes in the EP400
protein, mutation significances were scored using SIFT27,
PROVEN28, MutationTaster29, and M-CAP30. The Pre-
dictor of Natural Disordered Regions (PONDR) algorithm
was used to predict disordered protein regions (http://
www.pondr.com/pondr-tut1.html)31–33.
Single-locus association test with deleterious variants
To identify unique deleterious variants in EP400 that were
associated with schizophrenia, we tested the accumulation
of 23 deleterious variants identified by target sequencing.
We used Fisher’s exact test to estimate P-values. The
significance threshold was 0.002174, with Bonferroni
correction.
Gene-based rare-variant association tests
To test differences in the burden of the candidate gene,
we used Efficient and Parallelizable Association Container
Toolbox (EPACTS) algorithms, which provide three dif-
ferent analyses (combined multivariate and collapsing
[CMC]34, Madsen–Browning35, and optimal sequence
kernel association test [SKAT-O]36). We excluded com-
mon variants with alternative allele frequencies > 0.005 in
any public database (1000 Genomes Project, all popula-
tion data released October 2014;37 NIH NHLBI 6 515
exome data [http://evs.gs.washington.edu/EVS/]; Exome
Aggregation Consortium 65 000 exome data;38 HGVD
exome data of 1 208 individuals in Japan;39 and SNV allele
frequency in whole-genome sequencing data of 2049
healthy Japanese individuals [https://ijgvd.megabank.
tohoku.ac.jp]) and >0.005 in our in-house control sam-
ples, with a call rate <90% or genotyping quality <99. We
selected four histone-modifying genes (the histone
Table 1 Clinical presentation of the Japanese family including multiple patients.





ICD-10 DSM-5 I II III IV V
I-9 47 F20.00 295.90 2 2 3 1 3 45 HPDa –
II-3 21 F20.00 295.90 3 3 4 1 4 15 HPD, ZTN, CHP, OLZ, QUE, RIS TRS
II-5 34 F20.04 295.90 3 2 2 1 3 45 RIS*, OLZ, QUE –
II-12 18 F20.00 295.90 2 2 2 0 3 45 HPD*, OLZ, QUE, RIS –
II-17 17 F20.10 295.90 3 3 4 2 4 15 HPD, OLZ, QUE, RIS TRS
III-2 17 F20.10 295.90 1 1 3 1 4 35 – No consent for drug treatment
III-3 30 F20.01 295.90 2 2 1 0 2 65 OLZa –
Diagnosis: ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th edition, DSM-5: Diagnostic and Statistical Manual of Mental
Disorders, 5th Edition; F20.00: paranoid schizophrenia, continuous; F20.01: paranoid schizophrenia, episodic with progressive defect; F20.04: paranoid schizophrenia,
incomplete remission; F20.10: hebephrenic schizophrenia, continuous; 295.90: schizophrenia. Clinician-Rated Dimensions of Psychosis Symptom Severity: I:
hallucinations, II: delusions, III: disorganised speech, IV: abnormal psychomotor behaviour, V: negative symptoms. GAF: Global Assessment of Functioning Scale.
Medications: HPD: haloperidol, ZTN: zotepine, CHP: chlorpromazine, OLZ: olanzapine, QUE: quetiapine, RIS: risperidone. Other: TRS: treatment-resistant schizophrenia.
aDrugs that improved the GAF scale over 40.
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deacetylase 4 [HDAC4] gene, the lysine methyltransferase
2D [KMT2D] gene, the lysine demethyltransferase 6A
[KDM6A] gene, and the nuclear receptor binding SET
domain protein 1 [NSD1] gene) as controls. The sig-
nificance threshold was set to 0.01, with Bonferroni
correction.
Generation of Ep400 knock-in mice
We designed guide RNA onto exon 47 of mouse ortholog
Ep400, corresponding to the mutation position in the family
from the present study. Single-guide RNA was designed
using the ATUM gRNA Design Tool (https://www.atum.
bio/eCommerce/cas9/input) as follows: 5′-CACTTGC
GCTGGTTGCTGTG-3′. Single-strand DNA oligonucleo-
tides (ssODN) to introduce mutations into mouse DNA






Single-guide RNA, crRNA, tracrRNA, HiFi Cas9 (IDT
Inc, Coralville, IA, USA), and ssODN (FASMAC, Kana-
gawa, Japan) were mixed according to the mouse zygote
microinjection protocol provided by IDT Inc., and were
then injected into C57BL/6N zygotes using a micro-
injector (Olympus IX70 Fluorescence Microscope Cut-
away, Olympus, Tokyo, Japan), TransferMan NK2
(Eppendorf, Hamburg, Germany), FemtoJet 4i (Eppen-
dorf), and CellTram Oil (Eppendorf). Next, zygotes were
cultured until the two-cell stage in vitro and transferred to
recipient pseudopregnant female oviducts. PCR was used
to verify genotypes from mouse DNA using KOD FX Neo




Fresh mouse brains and spinal cords were fixed in 10%
formalin for 72 h, embedded in paraffin, and sectioned at
5-µm intervals. After deparaffinisation, slides were stained
with haematoxylin and eosin (HE) to visualise structures.
The Klüver–Barrera (KB) stain was used to detect myelin
sheaths. We viewed and photographed sections using a
BZ-9000 All-in-One Fluorescence Microscope (Keyence,
Osaka, Japan). For immunohistochemical staining, tissue
slides were deparaffinised, rehydrated, and rinsed in Tris-
buffered saline (TBS). For antigen retrieval, tissue sections
were microwaved for 20 min in 10 mM citrate buffer
using an MI-77 microwave processor (Azumaya Cor-
poration, Tokyo, Japan). Sections were then blocked in
Protein Block Serum-Free (Dako, Carpinteria, CA, USA)
for 1 h at room temperature, followed by incubation with
primary and secondary antibodies for 1 h each at room
temperature. Immunofluorescent staining was performed
using the following primary antibodies: polyclonal anti-
EP400 (HPA016704, Atlas Antibodies, Bromma, Sweden)
and polyclonal anti-MAP2 (ab5392, Abcam, Cambridge,
UK). Secondary antibodies were goat anti-chicken IgY
H&L Alexa Fluor 488 (ab150169, Abcam) and goat anti-
rabbit IgG H&L Alexa Fluor 555 (ab150078, Abcam).
Primary and secondary antibodies were diluted using
Antibody Diluent with Background Reducing Compo-
nents (Dako). Sections were mounted with Vectashield
Mounting Medium for fluorescence analysis with DAPI
(Vector Laboratories, Burlingame, CA, USA). Fluorescent
images were taken using a BZ-9000 All-in-One Fluores-
cence Microscope (Keyence).
Transmission electron microscopy (TEM)
Samples were fixed with 2% glutaraldehyde (Nacalai
Tesque, Kyoto, Japan) in 0.1M sodium cacodylate buffer
containing 1mM CaCl2 and 1mM MgCl2 (cacodylate
buffer, pH 7.4) at room temperature for 72 h, rinsed with
cacodylate buffer, and post-fixed with 1% OsO4 (Nacalai
Tesque) in cacodylate buffer at 4 °C for 60min. Next,
samples were washed with cacodylate buffer, dehydrated
in a graded series of ethanol and acetone, and embedded
in Quetol 651 epoxy resin (Nisshin EM, Tokyo, Japan).
The blocks were then sectioned at 5-µm intervals and
stained with toluidine blue (TB) to visualise myelin
sheaths. Resin-embedded samples were further trimmed
and sectioned using a diamond knife on an ultra-
microtome (Reichert-Jung, Vienna, Austria). Ultra-thin
sections were collected on grids, stained with uranyl
acetate and lead citrate, and examined at 80 kV by TEM
(JEM-1230; JEOL, Tokyo, Japan). Axon diameters and G-
ratios of randomly selected axons in the white matter of
the spinal cord were measured using ImageJ (axon dia-
meter, n= 100; G-ratio, n= 30)40,41. The two-sided F-test
was applied to confirm normally distributed data. The
two-sided Student’s t-test and two-sided Welch’s t-test
were applied for comparison. The significance threshold
was set to 0.05.
Neurobehavioural screening battery in Ep400 knock-in
mice
The mice used in the present study were derived from
backcrossing to C57BL/6N for five generations. Six male
Ep400-p.P2715L#1 mice and six male wild-type (WT)
littermates were examined using behavioural tests at 3
and 6 months old. Mice were housed individually at
22 °C–26 °C, humidity 40%–65%, and 12-h light/dark
periods. Hindlimb clasping: a marker of disease progres-
sion in a number of mouse models of neurodegenera-
tion42,43. We evaluated hindlimb clasping scores using the
following criteria44. Hindlimbs were consistently splayed
outward, away from the abdomen= 0. One hindlimb was
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retracted toward the abdomen for more than 50% of the
time suspended= 1. Both hindlimbs were partially
retracted toward the abdomen for more than 50% of the
time suspended= 2. Hindlimbs were entirely retracted
and touching the abdomen for more than 50% of the time
suspended= 3. Open-field test: measures locomotor
activity, exploratory drive, neophobia, and certain aspects
of anxiety45. Mice were placed in a clean box measuring
50 × 50 × 40 cm. The central area was 60% of the area.
After 15 min resting time, mice were placed peripherally
in the box facing outward, and were observed for 10 min
by video tracking. Video data were analysed using Bara-
Baby X (LNSOFT, Tokyo, Japan). Migration length (cm)
was measured as horizontal activity. Centre time was
calculated as the ratio of movement time in the central
area to the entire movement time. Social interaction test:
evaluates social behaviour phenotypes by placing two
animals in a neutral cage and measuring the percentage of
time spent in direct physical contact, including ano-
genital exploration, sniffing with direct contact, crawling,
grooming, and play behaviour46. Mice were kept in cages
for 7 days to prepare, and stimulator mice were then put
into the same cage as the subject mice under video
monitoring. After 15 min, stimulator mice were removed,
and video monitoring was stopped. Movies were analysed
using BORIS Software 4.1.4 (https://www.boris.unito.it)47.
Y-maze test: evaluates short-term spatial working mem-
ory48. After 15 min resting time, mice were placed on one
corner of an arm of the apparatus, facing the outer side,
under video monitoring. Mice were monitored for 10 min
without stimulation, and the number of entries into each
of three arms was counted. Spontaneous alternations were
calculated if the mouse entered three different arms
sequentially. Rotarod test: evaluates motor coordination49.
Mice in a “stable state” after 20 min rest were placed on
the rotarod (Rota-Rod Treadmill for Mice, Model MK-
610A, Muromachi Kikai, Tokyo, Japan) at 4 rpm. After
several seconds, the rotor accelerated to 40 rpm for 300 s.
Tests were repeated up to three times if mice fell off
before 10 s had passed (Trial 1). After 20 min, the same
tests were again administered (Trial 2). An two-sided F-
test confirmed normally distributed data and two-sided　
Student’s t-test was used for two-sample significance
tests. The significance threshold was set to 0.05. All
behavioural testing was performed by Unitech Co., Ltd.
(Chiba, Japan).
Results
WES and variant filtering
We identified a large Japanese family with autosomal
dominant inheritance of schizophrenia. The patients in
this family exhibited severe negative symptoms and low
scores in the Global Assessment of Functioning Scale
(Clinician-Rated Dimensions of Psychosis Symptom
Severity: Vaverage= 3.29; Global Assessment of Function-
ing Scale: GAFaverage= 37.9). Of the patients in this
family, two second-generation TRS patients (II-3 and II-
17) responded poorly to antipsychotics and required
multiple long-term hospitalisations (Table 1). To identify
potential pathogenic genetic variants, we performed WES
on 10 family members (affected: I-9, II-3, II-5, II-12, II-17,
III-2, III-3; unaffected: I-13, II-11, II-20; Fig. 1a). Using
NGS, we detected 148,069 variants, of which 2176 var-
iants were annotated to be deleterious (Supplementary
Table 3). Of the 2 176 deleterious variants, only two
variants, on chromosome 12q24.3, were completely seg-
regated with schizophrenia (chr12:123311084, T>C
[rs768213554] in SBNO1; and chr12:132064747, C>T
[rs200626129] in EP400; Supplementary Tables 2, 3).
Next, we screened these two substitutions in 445 healthy
Japanese individuals and found that rs768213554 in
SBNO1 gene was present in healthy controls, as well as in
two Japanese public databases (control cohort: minor
allele frequency [MAF]= 0.0022; HGVD v2.30: MAF=
0.00124; 4.7KJPN: MAF= 0.0012). Because the patho-
genic mutation in this family was expected to have an
extremely high effect size and penetrance rate of Men-
delian inheritance, we excluded rs768213554 in SBNO1
from the candidate variants. Notably, mutation screening
indicated that rs200626129 in EP400 (confirmed by direct
sequencing; Fig. 1b) was a ‘unique’ variant, because it was
a novel variant in both healthy controls and Japanese
databases (control cohort: MAF= none; HGVD2.30:
MAF= none; 4.7KJPN: MAF= none; Supplementary
Tables 2, 3).
The position of the familial mutation, in exon 48 of the
EP400 gene, was located within a disordered binding region
that is highly conserved among mammals (Fig. 1c). We
next analysed whether rs200626129 in EP400 affects pro-
tein function, using SIFT, PROVEN, MutationTaster, and
M-CAP. All programs evaluated the variant as ‘damaging’
(SIFT score= 0.007, deleterious; PROVEN score=−2.67,
deleterious; MutationTaster score= 0.994, disease-causing;
M-CAP score= 0.254, damaging). The CaN-XT algorithm
in PONDR predicted that the variant would elongate the
disordered region of the EP400 protein (Fig. 1d). These
findings suggest that rs200626129 in EP400 causes dys-
function of the protein, and that this variant is relevant to
the pathogenesis of schizophrenia.
The rs200626129 variant in EP400 was considered to be
the pathogenic variant in this family because of its
uniqueness and complete linkage, although its genetic
burden in the development of schizophrenia and its
pathogenic effects on CNS functions were not evaluated.
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Single-locus association test with the deleterious variants
identified by EP400 sequencing
To evaluate the MAF of rs200626129 in sporadic schi-
zophrenia, and to identify other unique deleterious variants
in EP400 that are associated with schizophrenia, we per-
formed target capture sequencing of EP400 in Japanese
individuals with or without schizophrenia (schizophrenia: n
= 285; controls: n= 445). Notably, rs200626129 in EP400
was not identified in the 285 schizophrenia patients.
Nevertheless, we identified 23 deleterious variants in
EP400 using targeted sequencing. Of these 23 variants, 6
were novel variants that were not registered in databases
(HGVD2.30, 4.7KJPN, or gnomAD exome), 10 were ultra-
rare variants that were registered in at least one database
with MAF < 0.001, and 7 were rare variants registered in
at least one database with 0.001 <MAF < 0.005. None of
the 23 single loci had a significant association with schi-
zophrenia (Fig. 1e, Supplementary Table 4).
Gene-based rare-variant association tests
Schizophrenia patients had a tendency toward a higher
frequency of deleterious variants (7.37%) compared with
controls (3.15%; Table 2). To confirm the higher fre-
quency of deleterious variants in EP400 in patients with
schizophrenia compared with controls, we performed
gene-based rare-variant association tests using EPACTS
algorithms. We selected four histone-modifying genes
(HDAC4, KMT2D, KDM6A, and NSD1) as controls. In the
gene-based rare-variant association tests, EP400 showed
the lowest P-values in the five tested genes, but did not
show significant enrichment of rare variants in schizo-
phrenia (CMC, P= 0.059184; Madsen–Browning, P=
0.051225; SKAT-O, P= 0.010889; Table 2).
Generation of Ep400-p.P2715L mice using CRISPR/Cas9
technology
To reveal the functional significance of the familial
mutation in brain morphology and behavioural
characteristics, we generated two lines of Ep400P2715L/
P2715L mice (Ep400-p.P2715L#1 and #2), corresponding to
the human P2805L mutation, using CRISPR/Cas9. The
Ep400-p.P2715L#1 mice were born at a predicted ratio by
Mendelian segregation (Supplementary Table 5) and did
not show any differences in body size compared with
controls (3 months old: Student’s t-test, P= 0.1304;
6 months old: Student’s t-test, P= 0.07203; Fig. 2a, Sup-
plementary Table 6). According to public databases, the
EP400 protein is expressed in the brains of both mice and
humans50,51. Furthermore, our immunofluorescent stain-
ing results confirmed the expression of EP400 in 3-
month-old mouse brains, especially in neural cell nuclei.
However, there were no differences in EP400 protein
expression patterns between the knock-in mice and their
WT littermates (Supplementary Fig. 1).
Screening analysis for the known phenotypes of Ep400
conditional-knockout mice (hindlimb clasping and myelin
abnormalities) using Ep400-p.P2715L mice
Recent studies have reported distinctive phenotypes in
Ep400 conditional-knockout mice (notably, hindlimb
clasping and myelin abnormalities)52,53. Thus, to investi-
gate the possibility that the p.P2715L mutation also causes
Ep400 protein dysfunction in vivo, we screened our
Ep400-p.P2715L mice for these known phenotypes of
Ep400 conditional-knockout mice.
The Ep400-p.P2715L#1 mice showed peculiar hindlimb
clasping from 3 months of age (hindlimb clasping score,
WTaverage= 0.5; Ep400-p.P2715L#1average= 1.833; Stu-
dent’s t-test, P= 0.046; Fig. 2b, Supplementary Table 7,
Supplementary Video 1), which is a sign that is observed
in mice with CNS dysfunction and is used as a marker of
disease progression in a number of mouse models of
neurodegeneration42,43. This behaviour was also present
in Ep400-p.P2715L#2 mice (hindlimb clasping score,
Ep400-p.P2715L#2average= 2; Student’s t-test, P= 0.023;
Supplementary Fig. 2a, Supplementary Table 7).
Table 2 Rare variants in gene-based burden tests for EP400.
Gene Count of rare deleterious
variants
Frequency of rare variants in
SCZ subjects (n= 285)
Frequency of rare variants in







EP400 21 14 7.37% 3.15% 0.059 0.051 0.011
HDAC4 6 8 2.11% 1.80% 0.955 0.959 0.36
KMT2D 35 37 12.28% 8.31% 0.358 0.288 0.194
KDM6A 9 7 3.16% 1.57% 0.304 0.295 0.395
NSD1 13 18 4.56% 4.04% 0.644 0.648 0.834
The significance threshold was 0.01, with Bonferroni correction. SCZ: schizophrenia; CMC: combined multivariate and collapsing; SKAT-O: optimal sequence kernel
association test.
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Fig. 2 Screening analysis of known phenotypes in Ep400-p.P2715L mice. a Body weight of Ep400-p.P2715L#1 mice and their WT littermates (p.
P2715L#1 mice: n= 6, WT: n= 6). There was no significant difference in body weight in adult mice. b Genotype and hindlimb clasping. Sanger
sequencing was used to confirm the missense mutation (p.P2715L, red arrow) and synonymous mutation to break the protospacer adjacent motif
(PAM; green arrow) in Ep400. Hindlimb clasping (yellow arrow) was used as a marker of CNS dysfunction (p.P2715L#1 mice: n= 6, WT: n= 6). c In a
low-power field, there was no obvious differences in KB-stained tissue between 3-month-old Ep400-p.P2715L#1 mice and their WT littermates.
Ep400-p.P2715L#1 mice showed a decrease in axon diameters in the spinal marrow by both KB and TB staining in a high-power field. Ep400-p.
P2715L#1 mice did not show any morphological abnormalities in myelin sheaths in the TEM analysis (p.P2715L#1 mice: n= 2, WT: n= 2). KB/L=
Klüver–Barrera staining, in a low-power field. KB/H= Klüver–Barrera staining, in a high-power field. TB= Toluidine blue staining. Yellow scale bar=
200 µm. White scale bar= 50 µm. Green scale bar= 10 µm. Red scale bar= 1 µm. d TEM analysis was used to compare axon diameters and G-ratios
between Ep400-p.P2715L#1 and WT mice. A significant decrease in axon diameter in Ep400-p.P2715L#1 mice was confirmed by TEM analysis. Ep400-
p.P2715L#1 mice did not show significant differences in G-ratios compared with their WT littermates (p.P2715L#1 mice: n= 2, WT: n= 2).
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EP400 is expressed in all cell types in the developing
rodent CNS, and EP400-dependent SWR chromatin
remodelling activity is required for myelination. Hypo-
myelination and myelin abnormalities have been pre-
viously reported in the central and peripheral nervous
systems of oligodendrocyte-specific Ep400 conditional-
knockout mice52,53. Of note, we observed decreased axon
diameters in the knock-in mice compared with the WT
mice in KB and TB staining. However, there were no
morphological abnormalities in the myelin sheaths of
Ep400-p.P2715L#1 mice (Fig. 2c). Axon diameters
were significantly decreased in the Ep400-p.P2715L#1
mice under TEM (WTaverage= 4.9313 µm, Ep400-p.
P2715L#1average= 3.735 µm; Welch’s t-test, P= 3.71769E-
05; Fig. 2d). However, TEM analysis indicated no differ-
ences in G-ratios (diameter of naked axon/diameter of
myelinated axon) in the Ep400-p.P2715L#1 mice com-
pared with their WT littermates (WTaverage= 0.7143,
Ep400-p.P2715L#1average= 0.7506; Student’s t-test, P=
0.0732; Fig. 2d). The histological features of Ep400-p.
P2715L#2 mice were the same as those of Ep400-p.
P2715L#1 mice (Supplementary Fig. 2b, c).
HE staining of CNS tissue from Ep400-p.P2715L mice
We used histological methods to examine morpholo-
gical abnormalities in the CNS of Ep400-p.P2715L#1
mice, and observed no clear differences (e.g., abnormal-
ities in cortical structure, neuronal dropout, or cortical
atrophy) in HE-stained tissue from these mice compared
with their WT littermates (Supplementary Fig. 3a, b).
Neurobehavioural screening battery in Ep400-p.P2715L
mice
To date, there have been no reports of the effects of
Ep400 dysfunction on neurobehavioural phenotypes.
Thus, to evaluate the potential impact of EP400-p.P2715L
protein expression in the CNS on neurobehavioral phe-
notypes, we screened for neurobehavioural abnormalities
using a neurobehavioural screening battery, which con-
sisted of four different tests (the open-field, Y-maze,
rotarod, and social interaction tests). The open-field test
showed no significant differences in behaviour between 3-
month-old Ep400-p.P2715L#1 mice and WT littermates.
However, 6-month-old Ep400-p.P2715L#1 mice showed
significantly decreased central time (WTaverage= 36.8 s,
Ep400-p.P2715L#1average= 20.4 s; Student’s t-test, P=
0.018; Fig. 3a). The social interaction test also revealed no
significant differences between 3-month-old Ep400-p.
P2715L#1 mice and WT littermates. In contrast, 6-
month-old Ep400-p.P2715L#1 mice hesitated to approach
the stimulator mice and showed a significantly increased
number of stretched approaches compared with WT lit-
termates (WTaverage= 0.333, Ep400-p.P2715L#1average=
2.5; Student’s t-test, P= 0.0265; Fig. 3b, Supplementary
Video 2). These data suggest that Ep400-p.P2715L#1 mice
develop anxiety-like behaviours with age. The Ep400-p.
P2715L#1 mice showed no significant behavioural
abnormalities in the Y-maze or rotarod tests at any age
(Fig. 3c, d).
Discussion
We identified a possible novel schizophrenia-causing
gene in a Japanese family containing multiple members
affected with severe schizophrenia/TRS. Using WES, a
unique missense variant in EP400 was identified that
completely segregated with disease in this family.
Few studies have reported an association between
EP400 and psychiatric disorders. Prados et al. reported
that a DNA methylation status change of EP400 was
associated with borderline personality disorder54. How-
ever, no study has yet reported an association between
EP400 and schizophrenia. We performed a case–control
analysis to investigate the association between EP400
deleterious mutations and schizophrenia. The single-
variant association test indicated that deleterious variants
in EP400 were not significantly associated with schizo-
phrenia. Moreover, in gene-based rare-variant association
tests, EP400 did not show significant enrichment of rare
variants in schizophrenia. These results, together with the
absence of the identified familial mutation (rs200626129)
in 285 schizophrenia patients, suggest that rare variants in
EP400 do not account for a large subgroup of schizo-
phrenia patients.
Recent investigations have demonstrated the extreme
difficulty of identifying individual genes with significant
associations in rare-variant association studies17,18. For
example, Genovese et al.55 failed to implicate any specific
gene (including EP400) in schizophrenia, and only one
exome study to date, which investigated approximately
15,000 exomes, has been successful in reporting an indi-
vidual risk gene (SETD1A) for schizophrenia15. Given
these findings, the present study likely lacked the statis-
tical power needed to support rare-variant accumulation
because of its small sample size. Our study concept was
based on the rare variants’ contribution with relatively
high impact effect; thus, a large sample size is necessary
for rare-variant association studies56. To explore the
association between rare EP400 variants and schizo-
phrenia via rare-variant association studies, further ana-
lyses with larger sample sizes (>10,000, with multi-ethnic
populations) are required.
Ep400-p.P2715L mice, corresponding to the human
P2805L mutation, showed anxiety-like behaviour and had
decreased axon diameters in the spinal cord white matter.
These results reflect the successful use of mice to
demonstrate that the mouse P2715L mutation causes
histological and neurobehavioural abnormalities, which
may help to explain the pathogenesis of the human
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P2805L mutation in the family that was investigated in the
present study. Anxiety is not a main symptom of schi-
zophrenia but is sometimes observed in patients with this
disease57,58. In addition, some studies have reported
myelin and axon abnormalities in the white matter of
schizophrenia patients59,60. These reports, therefore,
indicate that our mouse model may mimic at least some
of the biological aetiologies of this family. However, the
phenotypes observed in Ep400 gene-edited mice in the
present study are not likely to be easily generalisable,
especially considering that the burden of rare variants in
EP400 on the development of schizophrenia remains
unclear. In addition, because the present study was lim-
ited to screening only, it is necessary to analyse whether
there are any unknown phenotypes in these mice, and
whether they show appropriate phenotypes to be con-
sidered a model of schizophrenia.
EP400 is the central ATP-hydrolysing subunit of the
TIP60/EP400 complex61,62, which is thought to exchange
histone H2A for H2A.Z in nucleosomes (especially in gene
regulatory regions such as promoters63–65) to influence
gene expression and DNA repair66. However, the mole-
cular functions of EP400 in the CNS are poorly char-
acterised. Elsesser et al. reported that EP400 interacts with
the transcription factor SOX10, binds to myelin regulatory
factor (MYRF) gene regulatory regions, and induces this
central transcriptional regulator of myelination52. Mutual
interactions between oligodendrocytes and neurons con-
trol the myelination and maturation of neural axons67–69.
Accordingly, the p.P2715L mutation might decrease axon
Fig. 3 Neurobehavioural screening battery in Ep400 knock-in mice. Ep400-p.P2715L#1 mice and their WT littermates were examined using
behavioural tests (p.P2715L#1 mice: n= 6, WT: n= 6). a Open-field test. Horizontal activity and centre time were measured, and activity traces are
shown. The coloured squares represent the centre areas. b Social interaction test. Various social interaction behaviours were measured and
compared. c Y-maze test. The number of entries and the percentage of alternations were measured and compared. d Rotarod test. Time spent on the
rotarod before falling was measured and compared.
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diameter via the dysfunction of these mutual interactions
between oligodendrocytes and neurons in the developing
CNS. In addition, the p.P2715L mice partially replicated
the phenotype of Ep400 conditional-knockout mice that
had been reported previously. This result, together with
the finding that p.P2715L mice show a novel phenotype—
of reduced axon diameter—suggests that the p.P2715L
mutation may not simply cause a loss of function of the
EP400 protein (e.g., a gain-of-function or partial-loss-of-
function mutation). Further functional studies that con-
firm the abnormal functions of mutated EP400 in the
developing CNS are, therefore, required to reveal the
underlying pathogenic mechanisms.
In conclusion, we identified a unique missense variant
in EP400 through the exome sequencing of a Japanese
family containing multiple schizophrenia patients. The
histological and neurobehavioural abnormalities observed
in Ep400 gene-edited mice implicate the pathogenesis of
this familial mutation in the schizophrenia multiplex
family. The phenotypes of the Ep400 gene-edited mice
may not be generalisable, because the burden of rare
variants in EP400 on the development of schizophrenia
remains unclear. However, a better understanding of the
functional effects of EP400 in the CNS might help to
clarify both the pathophysiology of schizophrenia and the
development of new therapeutic targets for this disease.
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